Icecure Medical is trading 6.9% down at $2.79 after investors continued selling following the August 12, 2026, second-quarter earnings release, which reported revenue below analyst expectations.
- Adjusted loss was $1.80 per share versus a $1.50 forecast; revenue was $1.11 million versus $1.45 million expected, despite strong year-over-year growth.
- The decline follows consecutive regular-session losses on August 12 and August 13.